• Home

  • Documents

  • PowerPoint Presentation€¦ · and Her2 receptors by histopathology 83% Of TNBC patients have TP53...
26

PowerPoint Presentation€¦ · and Her2 receptors by histopathology 83% Of TNBC patients have TP53 mutations Genomic data has shown that T NBC patients ... Patients were treated

  • Upload
    others

  • View
    2

  • Download
    0

Embed Size (px)

Citation preview

Page 1: PowerPoint Presentation€¦ · and Her2 receptors by histopathology 83% Of TNBC patients have TP53 mutations Genomic data has shown that T NBC patients ... Patients were treated
Page 2: PowerPoint Presentation€¦ · and Her2 receptors by histopathology 83% Of TNBC patients have TP53 mutations Genomic data has shown that T NBC patients ... Patients were treated
Page 3: PowerPoint Presentation€¦ · and Her2 receptors by histopathology 83% Of TNBC patients have TP53 mutations Genomic data has shown that T NBC patients ... Patients were treated
Page 4: PowerPoint Presentation€¦ · and Her2 receptors by histopathology 83% Of TNBC patients have TP53 mutations Genomic data has shown that T NBC patients ... Patients were treated
Page 5: PowerPoint Presentation€¦ · and Her2 receptors by histopathology 83% Of TNBC patients have TP53 mutations Genomic data has shown that T NBC patients ... Patients were treated
Page 6: PowerPoint Presentation€¦ · and Her2 receptors by histopathology 83% Of TNBC patients have TP53 mutations Genomic data has shown that T NBC patients ... Patients were treated
Page 7: PowerPoint Presentation€¦ · and Her2 receptors by histopathology 83% Of TNBC patients have TP53 mutations Genomic data has shown that T NBC patients ... Patients were treated
Page 8: PowerPoint Presentation€¦ · and Her2 receptors by histopathology 83% Of TNBC patients have TP53 mutations Genomic data has shown that T NBC patients ... Patients were treated
Page 9: PowerPoint Presentation€¦ · and Her2 receptors by histopathology 83% Of TNBC patients have TP53 mutations Genomic data has shown that T NBC patients ... Patients were treated
Page 10: PowerPoint Presentation€¦ · and Her2 receptors by histopathology 83% Of TNBC patients have TP53 mutations Genomic data has shown that T NBC patients ... Patients were treated
Page 11: PowerPoint Presentation€¦ · and Her2 receptors by histopathology 83% Of TNBC patients have TP53 mutations Genomic data has shown that T NBC patients ... Patients were treated
Page 12: PowerPoint Presentation€¦ · and Her2 receptors by histopathology 83% Of TNBC patients have TP53 mutations Genomic data has shown that T NBC patients ... Patients were treated
Page 13: PowerPoint Presentation€¦ · and Her2 receptors by histopathology 83% Of TNBC patients have TP53 mutations Genomic data has shown that T NBC patients ... Patients were treated
Page 14: PowerPoint Presentation€¦ · and Her2 receptors by histopathology 83% Of TNBC patients have TP53 mutations Genomic data has shown that T NBC patients ... Patients were treated
Page 15: PowerPoint Presentation€¦ · and Her2 receptors by histopathology 83% Of TNBC patients have TP53 mutations Genomic data has shown that T NBC patients ... Patients were treated
Page 16: PowerPoint Presentation€¦ · and Her2 receptors by histopathology 83% Of TNBC patients have TP53 mutations Genomic data has shown that T NBC patients ... Patients were treated
Page 17: PowerPoint Presentation€¦ · and Her2 receptors by histopathology 83% Of TNBC patients have TP53 mutations Genomic data has shown that T NBC patients ... Patients were treated
Page 18: PowerPoint Presentation€¦ · and Her2 receptors by histopathology 83% Of TNBC patients have TP53 mutations Genomic data has shown that T NBC patients ... Patients were treated
Page 19: PowerPoint Presentation€¦ · and Her2 receptors by histopathology 83% Of TNBC patients have TP53 mutations Genomic data has shown that T NBC patients ... Patients were treated
Page 20: PowerPoint Presentation€¦ · and Her2 receptors by histopathology 83% Of TNBC patients have TP53 mutations Genomic data has shown that T NBC patients ... Patients were treated
Page 21: PowerPoint Presentation€¦ · and Her2 receptors by histopathology 83% Of TNBC patients have TP53 mutations Genomic data has shown that T NBC patients ... Patients were treated
Page 22: PowerPoint Presentation€¦ · and Her2 receptors by histopathology 83% Of TNBC patients have TP53 mutations Genomic data has shown that T NBC patients ... Patients were treated
Page 23: PowerPoint Presentation€¦ · and Her2 receptors by histopathology 83% Of TNBC patients have TP53 mutations Genomic data has shown that T NBC patients ... Patients were treated
Page 24: PowerPoint Presentation€¦ · and Her2 receptors by histopathology 83% Of TNBC patients have TP53 mutations Genomic data has shown that T NBC patients ... Patients were treated
Page 25: PowerPoint Presentation€¦ · and Her2 receptors by histopathology 83% Of TNBC patients have TP53 mutations Genomic data has shown that T NBC patients ... Patients were treated
Page 26: PowerPoint Presentation€¦ · and Her2 receptors by histopathology 83% Of TNBC patients have TP53 mutations Genomic data has shown that T NBC patients ... Patients were treated

OSE:BGBIO Result First Quarter 2018 - BerGenBio · previously treated TNBC patients and 18% in NSCLC. PD-L1 negative patients remain particularly challenging. The BGBC007 and 008

OSE:BGBIO Result First Quarter 2018 - BerGenBio · previously treated TNBC patients and 18% in NSCLC. PD-L1 negative patients remain particularly challenging. The BGBC007 and 008

Documents
TP53 Certification – Round 2

TP53 Certification – Round 2

Documents
Potential Predictive Value of TP53 and Mutation …...TP53 and KRAS mutation for response to PD-1 blockade immunotherapy in lung adenocarcinoma. TP53 and KRAS Mutation Predicts Response

Potential Predictive Value of TP53 and Mutation …...TP53 and KRAS mutation for response to PD-1 blockade immunotherapy in lung adenocarcinoma. TP53 and KRAS Mutation Predicts Response

Documents
Adjuvant Chemotherapy TNBC & HER2 Subtype · 2015. 8. 28. · Adjuvant Chemotherapy TNBC & HER2 Subtype . Gun Min Kim . Yonsei Cancer Center . Division of Medical Oncology . Department

Adjuvant Chemotherapy TNBC & HER2 Subtype · 2015. 8. 28. · Adjuvant Chemotherapy TNBC & HER2 Subtype . Gun Min Kim . Yonsei Cancer Center . Division of Medical Oncology . Department

Documents
Terapia Neo-adiuvante: malattia triplo negativa Valentina ...media.aiom.it/userfiles/files/doc/AIOM-Servizi/... · N=1,320 •Study to start recruiting patients with TNBC; plan to

Terapia Neo-adiuvante: malattia triplo negativa Valentina ...media.aiom.it/userfiles/files/doc/AIOM-Servizi/... · N=1,320 •Study to start recruiting patients with TNBC; plan to

Documents
TP53 Mutations in Human Skin Cancers - The TP53 …p53.free.fr/Database/p53_cancer/Human_Mutation_p53/p53...p53 REVIEW ARTICLE TP53 Mutations in Human Skin Cancers Giuseppina Giglia-Mari

TP53 Mutations in Human Skin Cancers - The TP53 …p53.free.fr/Database/p53_cancer/Human_Mutation_p53/p53...p53 REVIEW ARTICLE TP53 Mutations in Human Skin Cancers Giuseppina Giglia-Mari

Documents
Neoadjuvant Interferons: Critical for effective PD-1 based … · 2018-01-14 · Abstract . The lack of targeted therapies available for triple-negative breast cancer (TNBC) patients

Neoadjuvant Interferons: Critical for effective PD-1 based … · 2018-01-14 · Abstract . The lack of targeted therapies available for triple-negative breast cancer (TNBC) patients

Documents
TNBC Supplementary Figure 1 d e f HD PEST Notch pathway activation (TNBC cases only) c a b NOTCH1 NOTCH2 NOTCH3

TNBC Supplementary Figure 1 d e f HD PEST Notch pathway activation (TNBC cases only) c a b NOTCH1 NOTCH2 NOTCH3

Documents
Nature Targeting Tp53 Cell Cycle

Nature Targeting Tp53 Cell Cycle

Documents
ERIC TP53 Network – activities and outcomes

ERIC TP53 Network – activities and outcomes

Documents
T-cell responses to TP53 'hotspot' mutations and …...tumor infiltrating lymphocytes in patients with metastatic ovarian cancer, sometimes at high frequencies and with multivalent

T-cell responses to TP53 'hotspot' mutations and …...tumor infiltrating lymphocytes in patients with metastatic ovarian cancer, sometimes at high frequencies and with multivalent

Documents
Comprehensive bioinformatics analysis of the TP53

Comprehensive bioinformatics analysis of the TP53

Documents
TP53 pathway in ovarian carcinoma subcutaneously ... · and TP53 pathway may be a new target for the treatment of ovarian cancer. Key Words: TP53 pathway, Ovarian carcinoma, p53,

TP53 pathway in ovarian carcinoma subcutaneously ... · and TP53 pathway may be a new target for the treatment of ovarian cancer. Key Words: TP53 pathway, Ovarian carcinoma, p53,

Documents
Endophilin A2 Promotes TNBC Cell Invasion and Tumor ......Signal Transduction Endophilin A2 Promotes TNBC Cell Invasion and Tumor Metastasis Tomas Baldassarre1,2, Kathleen Watt1,2,

Endophilin A2 Promotes TNBC Cell Invasion and Tumor ......Signal Transduction Endophilin A2 Promotes TNBC Cell Invasion and Tumor Metastasis Tomas Baldassarre1,2, Kathleen Watt1,2,

Documents
TNBC Risk Factors to Potential Targets

TNBC Risk Factors to Potential Targets

Documents
Supplementary Information Comprehensive molecular ...10.1038/s41467-020-175… · 3 ailed RNAse uality filters nrolled patients SCAN-B n3 patients 3 opulation-ased NBC TNBC cohort

Supplementary Information Comprehensive molecular ...10.1038/s41467-020-175… · 3 ailed RNAse uality filters nrolled patients SCAN-B n3 patients 3 opulation-ased NBC TNBC cohort

Documents
Gen TP53 & Gen RB Drg Maharani

Gen TP53 & Gen RB Drg Maharani

Documents
TP53 ABERRATIONS Methodical considerations · 2019-12-12 · TP53 aberrations: Methodical considerations TP53 gene in CLL: KEEP IN MIND In CLL, TP53 mutations are (1) frequently subclonal,

TP53 ABERRATIONS Methodical considerations · 2019-12-12 · TP53 aberrations: Methodical considerations TP53 gene in CLL: KEEP IN MIND In CLL, TP53 mutations are (1) frequently subclonal,

Documents
TNBC for Review Board

TNBC for Review Board

Documents
eprints.soton.ac.uk  · Web view2020. 10. 6. · Title: Breast cancer in patients with germline . TP53. pathogenic variants have typical tumour characteristics - the . Co. hort study

eprints.soton.ac.uk  · Web view2020. 10. 6. · Title: Breast cancer in patients with germline . TP53. pathogenic variants have typical tumour characteristics - the . Co. hort study

Documents
The Northern Boys Club | TNBC/010

The Northern Boys Club | TNBC/010

Documents
Space Heating Equipment Tp53

Space Heating Equipment Tp53

Documents
TNBC: (Neo) Adjuvant systemic therapy - OncologyPROoncologypro.esmo.org/content/download/122383/2314715/file/2017... · TNBC: (Neo) Adjuvant systemic therapy Javier Cortes, ... 49

TNBC: (Neo) Adjuvant systemic therapy - OncologyPROoncologypro.esmo.org/content/download/122383/2314715/file/2017... · TNBC: (Neo) Adjuvant systemic therapy Javier Cortes, ... 49

Documents
Triple-Negative Breast Cancer (TNBC)

Triple-Negative Breast Cancer (TNBC)

Documents
The Northern Boys Club | TNBC/011

The Northern Boys Club | TNBC/011

Documents
CytRx (CYTR) Corporate Presentation...The abstract includes data from three patients with third-line or greater TNBC and two patients with fourth-line or greater HNSCC. All treatment

CytRx (CYTR) Corporate Presentation...The abstract includes data from three patients with third-line or greater TNBC and two patients with fourth-line or greater HNSCC. All treatment

Documents
Triple-Negative Breast Cancer - Surgerysurgery.uthscsa.edu/research/TNBC-Hurd.pdfTriple negative breast cancer (TNBC) is biologically aggressive and is associated with a worse prognosis

Triple-Negative Breast Cancer - Surgerysurgery.uthscsa.edu/research/TNBC-Hurd.pdfTriple negative breast cancer (TNBC) is biologically aggressive and is associated with a worse prognosis

Documents
Evolving Therapeutic Algorithms for Patients with ...images.researchtopractice.com/2019/Meetings/... · Case Presentation: Dr Khan 49-year-old man •IGHV-mutated, del(17p)-and TP53-unmutated

Evolving Therapeutic Algorithms for Patients with ...images.researchtopractice.com/2019/Meetings/... · Case Presentation: Dr Khan 49-year-old man •IGHV-mutated, del(17p)-and TP53-unmutated

Documents
BRCA1/2 mutation prevalence among triple-negative breast cancer …... · 2014-03-13 · Background: BRCA1/2 mutation identification among triple-negative breast cancer (TNBC) patients

BRCA1/2 mutation prevalence among triple-negative breast cancer …... · 2014-03-13 · Background: BRCA1/2 mutation identification among triple-negative breast cancer (TNBC) patients

Documents
TP53 tradicion perenne 53

TP53 tradicion perenne 53

Documents